AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-IR Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multi-agent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing

ACNS1123:  Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors. 

The Effects of Harp Music on Anxiety, Depression, and Nausea in Cancer Patients Receiving Chemotherapy

ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754, IND#118613)

Quorum Novartis Signature study, CBGJ398XUS04: Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 6 – BGJ398 for patients with tumors with FGFR genetic

A phase II, Multicenter, Four-Cohort Study of Oral c-MET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (WT), Advanced Non-small Cell Lung Cancer (NSCLC) who have Received One or Two

A031201: Phase III Trial of Enzalutamide (NSC#766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Acute Myeloid Leukemia (ECOG #E2906): Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by

Leukemia (CA 180-330): Studying interventions for managing patients with chronic myeloid leukemia in chronic phase: the 5-year prospective cohort study (SIMPLICITY) (2_PRO00000118)

Leukemia (ECOG E3903): Ancillary laboratory protocol for the collection of diagnostic material on patients considered for ECOG treatment trials for leukemia or related hematologic disorders (2_PRO00000429)